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Background: Diabetes mellitus is a common chronic metabolic disorder and one of the main causes of death in
Palestine. Palestinians are continuously living under stressful economic and military conditions which make them
psychologically vulnerable. The purpose of this study was to investigate the prevalence of depression among type II
diabetic patients and to examine the relationship between depression and socio-demographic factors, clinical
factors, and glycemic control.
Methods: This was a cross-sectional study at Al-Makhfiah primary healthcare center, Nablus, Palestine. Two hundred
and ninety-four patients were surveyed for the presence of depressive symptoms using Beck Depression Inventory
(BDI-II) scale. Patients' records were reviewed to obtain data pertaining to age, sex, marital status, Body Mass Index
(BMI), level of education, smoking status, duration of diabetes mellitus, glycemic control using HbA1C test, use of
insulin, and presence of additional illnesses. Patients’ medication adherence was assessed using the 8-item Morisky
Medication Adherence Scale (MMAS-8).
Results: One hundred and sixty four patients (55.8%) of the total sample were females and 216 (73.5%) were < 65 years
old. One hundred and twenty patients (40.2%) scored ≥ 16 on BDI-II scale. Statistical significant association was found
between high BDI-II score (≥ 16) and female gender, low educational level, having no current job, having multiple
additional illnesses, low medication adherence and obesity (BMI≥ 30 kg/m2). No significant association between BDI
score and glycemic control, duration of diabetes, and other socio-demographic factors was found. Multivatriate
analysis showed that low educational level, having no current job, having multiple additional illnesses and low
medication adherence were significantly associated with high BDI-II scores.
Conclusion: Prevalence of depression found in our study was higher than that reported in other countries. Although
40% of the screened patients were potential cases of depression, none were being treated with anti-depressants.
Psychosocial assessment should be part of routine clinical evaluation of these patients at primary healthcare clinics to
improve quality of life and decrease adverse outcomes among diabetic patients.
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Diabetes mellitus (DM) is a common health problem
with serious medical and economic consequences. Be-
tween 2010 and 2030, there will be a 69% increase in
numbers of adults with diabetes in developing countries
and a 20% increase in developed countries [1]. The Arab* Correspondence: waleedsweileh@yahoo.com
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reproduction in any medium, provided the orworld (North Africa, Middle East, and Gulf area) will
have second highest increase in percentage of people
with DM in 2030 compared to other parts of the world
[1]. Few studies about prevalence of DM were carried
out in Palestine and showed a higher rate of this disease
in an urban community than in a rural community [2-4].
However, no reliable data exist for treatment, complica-
tions, economic effect, and outcomes of treatment of
DM in Palestine [5].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mately 340 million people worldwide suffer from depres-
sion at any given time [6]. A study designed to examine
the prevalence of mood disorders in 14 countries found
that the 12-month prevalence of mood disorders was low-
est in Nigeria and highest in the United States [7]. It was
estimated that depressive disorders were the fourth lead-
ing cause of disease burden in women and seventh leading
cause in men [8,9]. Major depression was found to be the
second leading cause of disability-adjusted life years
(DALYs) lost in women and the tenth leading cause of
DALYs in men [10]. In Palestine, psychological distress is
high, quality of life is very low, and daily life of Palestinians
is constantly under threat which make Palestinians more
vulnerable to stress and depression [5].
Relationship between DM and depression has been in-
vestigated by many researchers. Prevalence of depression
among individuals with DM appears to vary by type of
DM, race/ethnicity, and among developed and develop-
ing nations [11,12]. Therefore, screening for depression
among diabetic patients is important in different races
and ethnicities. Actually, studies indicated that about
49% of the diabetic patients having severe depression
were misrecognized on the primary healthcare clinics
[13,14]. Unfortunately, Palestinians with chronic diseases
are usually less likely to have regular sources of medical
care for screening or preventive services [15].
The aim of this study was to estimate the prevalence of
depression among Palestinian type 2 diabetic patients at-
tending primary healthcare settings and to describe socio-
demographic and clinical characteristics associated with
diabetic patients having depression. Given the scarcity of
research about depression among Palestinians in general
and among diabetic patients in particular, such study is
needed. The knowledge gained from this study will assist
healthcare practitioners to better understand depression
in diabetes mellitus and design treatments that address
the psychological and the metabolic needs of affected indi-
viduals to improve overall health outcomes.
Methods
Setting and design
This was a cross-sectional descriptive study for the pur-
pose of evaluating the presence of depression symptoms
and their association with glycemic control (HbA1C),
medication adherence, clinical and demographic vari-
ables among Palestinians with type 2 diabetes mellitus.
Nablus is the largest city in north West-Bank of
Palestine. Residents of Nablus city are predominantly
Arabs. The study was carried out at the governmental dia-
betes primary healthcare clinic (Al-Makhfia) in Nablus
city. There are five main healthcare providers of health
services in Palestine: Ministry of health, UNRWA, NGOs,
Palestinian Military Medical Services (PMMS) and Privatefor profit. MOH bears the heaviest burden, as it has the
major responsibility [16]. During the study period, the
investigator visited the primary healthcare center at Al-
Makhfia, Nablus. The visits were made on Sundays,
Tuesdays, Wednesdays and Thursdays every week. These
are the assigned days for diabetic clinics to deliver care
for patients with type II DM. Al-Makhfia center is the
only governmental center that provides care for diabetic
patients with governmental insurance in Nablus city. The
study was carried out from April to August 2012.
Sample population
This study included a convenience sample of adult
population. Participants were recruited from Al-Makhfia
diabetic clinics while waiting to be seen by their health
care providers. The inclusion criteria for this study were:
1) males and females 18 years old and older who self-
report being diagnosed with type 2 diabetes by a health
care provider and has a medical file at the diabetic clinic;
2) self-report type 2 diabetes for one year or longer;
3) under medical care for diabetes treatment according
to MOH documents; 4) able to understand the questions
in order to help complete forms and questionnaires;
5) willingness to participate in this study and finally
6) being scheduled to do HbA1c at the laboratory of
MOH at the time of the visit. The exclusion criteria were
based on self-report of the following: 1) physical and or
mental conditions that interfere with participation, and
2) inability to obtain venous blood sample.
Sample size
No studies about the prevalence of depression among
diabetic patients in Palestine have been reported. There-
fore, we estimated the sample size based on studies in
other Arab countries [17]. The sample size was esti-
mated based on the following assumptions: a descriptive
study with dichotomous outcome: the sample size tables
shows that a sample of 246 participants is needed if we
assume the prevalence of depression to be 20% and the
width of confidence interval to be 10% and the confi-
dence limit to be 95%.
Participant recruitment procedure
The investigators obtained written approval from MOH
to carry out this study. A brief screening for recruitment
of participants was conducted by the investigators to
identify potential participants in the following manner:
every person in the waiting area was asked if he is will-
ing to talk to the investigator. If the person agreed to
talk to the investigator for possible participation, the at-
tending specialist was asked if that person is scheduled
to do HbA1c at that visit. If the person who agreed was
scheduled to do HbA1c, then an informed consent was
read and obtained by the investigators at the diabetic
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sion and exclusion criteria took place. The questionnaires
required for the study were presented and explained for
its completion during this session. The forms and ques-
tionnaires that were completed included: 1) demographic
and clinical questionnaire to gain information on partici-
pant, 2) BDI-II to measure depressive symptoms), Morisky
Medication Adherence Scale (MMAS-8) to determine
level of medication adherence among participants.
An investigator, who is a graduate nursing student with
a long experience in nursing, was trained prior to initi-
ation of the study to assist in the recruitment and admin-
istration of questionnaires. Re-training of the investigator
who administered the questionnaire took place after the
first week of the research study based on the need to clar-
ify certain points in the questionnaire. All participants
completed the questionnaires in a private area in the
clinic. A venous blood test, in a non-fasting state, was
drawn for measuring the HbA1C during the same session.
A certified phlebotomist was available on site to obtain
the sample and forward it to official labs of the MOH. Re-
sults regarding HbA1c for each participant were available
to the PI within the same working day. Data collection
and the completion of questionnaires took place before
HbA1c test. A note was given to healthcare provider in
the clinic about each participant’s HbA1c results.
Instruments
Measure of depression symptoms
The presence of depression symptoms was evaluated
using the Beck Depression Inventory-Second Edition
(BDI-II) [18]. Beck Depression Inventory is a well-
known self-report instrument. Its original version (21
items) was introduced in 1961 and its reliability and val-
idity have been established across a broad spectrum of
clinical and non-clinical populations [19-25]. The BDI-II
is available in English and has been translated into
Arabic and validated for use to measure depression. The
BDI-II has been translated into Arabic and validated for
use to measure depression. Use Permission to use the
Arabic version of BDI-II was obtained from the author
who did the translation and validation [26,27].
The term “depression” in this study referred to the
self-report of depressive symptoms identified in the BDI-
II. The format of the BDI-II test is for the participants to
select and circle the number beside one of the four
phrases listed that best describes their state in the past
two weeks including the day the questionnaire is an-
swered. The instrument consists of 21-items/statements
that are self-reported and takes approximately 15 mi-
nutes to complete. The score ranges from 0 - 63 to de-
termine possible degree of depression symptoms. The
instrument developers established four groups of scores
and classified as the following: “minimal 0-13, mild 14-19, moderate 20-28, and severe 29-63” [18]. Scores provide
an estimate of the overall symptom severity of depression.
High scores indicate greater depressive symptoms. We
used the most commonly used cut-off scores for BDI of ≥
16 to indicate clinical depression [28]. It should be empha-
sized that high BDI II scores presented in this study are
not definitive diagnosis of depression. Rather, high scores
are indicative of the presence of depressive symptoms and
further clinical consultation to establish definitive diagno-
sis of depression is needed.
Serum glycated hemoglobin measure (HbA1C)
Glycated hemoglobin (HbA1c) is used to measure blood
glucose control over several months and provides an esti-
mate of how well diabetes has been controlled over the
last 2 or 3 months. It is the goal standard of care for deter-
mining potential risk for developing problems, such as ret-
inopathy, renal disease, cardiovascular disease, peripheral
neuropathy or stroke. Potential complications are espe-
cially true if HbA1C remains high for a long period of
time [29]. The goal for HbA1C in adults is < 7% [29].
Serum blood test for HbA1C was obtained on the same
day and in the same clinic site either before or immedi-
ately after completing the questionnaires depending on
time available in clinic. The blood sample was obtained by
venous puncture drawn by a certified phlebotomist and
sent to a designated local laboratory with coded identifica-
tion number. HbA1c determination for all samples was
done in the same laboratory by the same technician and
applying the same technique. The method used to deter-
mine HbA1c is NycoCard READER II, using the Boronate
affinity test principle. It is NGSP-certified method.
Medication adherence
Anti-diabetic Medication adherence was measured using
Morisky Medication Adherence Scale (MMAS-8) [30].
Approval to use and translate the MMAS-8 into Arabic
language was obtained from the developer. The transla-
tion was carried out according to standard forward and
backward method. The Arabic- translated version of
MMAS-8 was used in previous publication [31]. The
MMAS-8 is an eight items questionnaire designed to
measure medication adherence. It is composed of seven
Yes/No questions. Details of the Arabic translation and
its use were described previously [31]. The eighth ques-
tion is a 5-points likert scale. In this study, patients with
a total score of MMAS-8 less than 6 are considered to
have poor medication adherence.
Demographic and health questionnaire
A questionnaire was designed for this study to gain in-
formation that would assist in obtaining biographical
and health history of the participants. The contents in-
cluded personal descriptive data such as age, gender, years
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tion that may breach confidentiality of participants was
not be included. The inclusion of address was obtained
separately to be able to send results of HbA1C, if desired.
Information was obtained on medical history, current
pharmacological diabetes treatment, and whether treat-
ment for depression was in progress. The medical history
components is a list of nine illnesses commonly identified
with type 2 diabetes where the response is in a dichotom-
ous (yes/no) format with an option to write in additional
illnesses not included in the list. All the participants were
asked to report all the medications that they use on
chronic basis. For the purpose of this manuscript, pres-
ence of ischemic heart disease and/or congestive heart fail-
ure and/or arrhythmia are referred to collectively as
cardiac problems while the presence of any stage of
chronic kidney disease is referred to as renal problems.
The data reported by the participants regarding their med-
ications was validated through checking the computerized
system at the MOH which contained up-to-date informa-
tion about the patients and their medications. The ques-
tionnaire was available in Arabic language.
Data management and statistical analysis
Pre-analysis
During the pre-analysis phase, the data were coded to
maintain confidentiality for all participants. Participants
were given an identification number assigned by the PI for
use throughout the study. In order to carry out quantitative
statistical analysis, measurement for variables was estab-
lished. Demographic information and summative score of
the instruments was obtained as a continuous measure as
much as possible to ease the process of designation meas-
ure according to statistical analysis. The data were entered
onto an SPSS (Statistical Package for the Social Sciences)
statistical software was used for data analysis.
Statistical analyses
Descriptive statistics was carried out for all variables and
expressed as mean ± SD for continuous variables with
normal distribution. Non-normally distributed continu-
ous variables were expressed as median (Q1-Q3). Nor-
mality of the data was tested by Kolomogrov-Smirnov
test. Factors associated with depression scores > 16 were
analyzed with binary logistic regression followed by mul-
tiple logistic regression analysis. Variables that showed
significance in univariate analysis were included in mul-
tiple logistic regression analysis. The dependent variable
was depression scores (≥ 16 versus < 16). A p value of <
0.05 was considered statistically significant.
Protection of human subjects
The study was undertaken as part of a higher research de-
gree at An-Najah National University, Nablus, Palestine.The study protocol was approved by the ethics committee
called “Institutional Review Board” (IRB) of the college of
Medicine and Health Sciences, Palestine. The application
for ethics committee was submitted on May 01, 2012 and
the approval was obtained on June 04, 2012. The inter-
viewer explained the purpose of the study and procedures
and gained written informed consent before commencing
the interview. The participants were also informed that
their participation was voluntary and that they could with-
draw from the interview/study at any time without conse-
quences. The participants were also informed about
potential risks for participating in the study which were
few and included any of the following: (1) becoming fa-
tigued or nervous while completing the questionnaires,
(2) possibility of pain to site during needle stick, (3) a
hematoma at the venous puncture site, and/or (4) infec-
tion, although it is highly unlikely, from the needle stick.
The participants were assured that their responses would
be treated in confidence and they were assured anonymity
through the use of strict coding measures. All information
was kept confidential and consent forms were number
coded for identification. The research file will be kept for
five years after completion of the study. At the end of this
period, records will be destroyed appropriately. The study
was carried out in full compliance with the guidelines of
good clinical practice of the world assembly declaration of
Helsinki and was approved by the university ethical com-
mittee. Well informed consent was taken from all enrolled
patients.
Results
During the study period, approximately 1400 patients
visited the center and did the HbA1c test per required
by the physician. Many of those patients leave the clinic
immediately after taking the blood sample which made
them un-available for interview. A net total of 301 dia-
betic patients were available and agreed to do the inter-
view. Seven patients were excluded because of their
inability to communicate or understand the questions or
have sensory impairment like being deaf. A net of 294
type 2 diabetic patients met the inclusion criteria and
were interviewed and their HbA1c test was obtained.
The majority (216; 73.5%) of participants were younger
than 65 years old. Age was negatively skewed with a me-
dian (Q1 – Q3) age of 60 (52 – 66.25) years. The major-
ity (164; 55.8%) of participants was female. The largest
portion (n = 213, 72.5%) of participants reported being
either illiterate or had a limited school education while
those with college education were minority (n = 40;
13.6%). The marital status as reported by participants
was married (n = 243; 82.7%), single/divorced/widowed
(n = 51, 17.3%). A small proportion (n = 62, 21.1%) of the
participants reported that they have a current job. The
majority (n = 223, 75.9%) of participants were non-
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number of years since diagnosis with type 2 diabetes which
showed a wide distribution ranging from 5 – 35 years,
positive skewness with a median (Q1 – Q3) of 10 (5 – 16)
years. The Body Mass Index (BMI) of the participants
showed positive skewness with a median (Q1 – Q3) of 30.6
(27.2 – 35.1). The BMI for males was 28.8 (26.6 – 33.8)
while that for females was 32 (28.3 – 37.4). The difference
in BMI between males and females was significant (P <
0.01) with a Z score of – 3.44. More than half (166; 56.5 %)
of the participants had a BMI ≥ 30. Both systolic and dia-
stolic blood pressures (SBP, DBP) showed positive skew-
ness. The median (Q1 – Q3) values for SBP and DBP were
132 (120 – 143) and 80 (75 – 88) mmHg respectively.
The number of diabetes medications reported by par-
ticipants ranged from 0-3 types with a median (Q1 – Q3)
of 2 (1 – 2) medications. One hundred and forty seven
(50%) reported insulin use either as a monotherapy or in
combination with other medications for diabetes man-
agement. Two hundred and sixty participants acknowl-
edged having additional illnesses along with diabetes.
The number of additional illnesses ranged from 1 – 5
with a median (Q1 – Q3) of 2 (1 - 3). The most common
chronic illness reported by the participants was high
cholesterol (n = 219, 74.5%), followed by hypertension
(n = 178, 60.5%), cardiac problems (n = 84, 28.6%) and
renal problems (37, 12.6%). In the reported medical his-
tory, none of the participants recalled being informed
that they had depression. Additionally, none of the par-
ticipants reported taking medications for depression.
The results for HbA1C ranged from 5.2 to 13%, a me-
dian (Q1 – Q3) of 8.2% (7.2 – 9.1). The median and mean
scores of HbA1C exceed the recommendation of < 7.0%
established by the ADA [29]. The results were un-equally
distributed with 3 extreme scores representing HbA1C be-
tween 12 and 13%. The HbA1C results were further di-
vided into two categories: controlled (< 7%) and
uncontrolled (≥ 7.0%). The percentage of participants who
had a controlled glucose was 17.7% (n = 52). However,
82.3% (n = 242) were in the uncontrolled level which
places individuals at a greater risk for developing diabetic
complication.
The depression symptoms score distribution was posi-
tively skewed with the majority of participants [n = 174,
59.2%] scored less than 16 while 120 (40.2%) patients
scored ≥ 16 in the depression scale. Medication adherence
scores were negatively skewed. The median value for
medication adherence scores was 5.8 (4.8 – 6.8). The ma-
jority (n = 167, 56.8%) of the participants had low adher-
ence scores (MMAS-8 < 6). Table 1 shows univariate
analysis of demographic and clinical factors with depres-
sion scores. The analysis showed that female diabetic pa-
tients, low level of education, having no current job,
having higher number of additional illness, low medicationadherence score and having high BMI were significantly
associated with depression score of ≥ 16. Multivariate
analysis (Table 2) showed that: 1) diabetic patients with
college education were less likely to have depression
[O.R = 0.24; (0.09 – 0.66)] than those with lesser level of
education, 2) diabetic patients with no current job were
more likely to have depression [O.R = 2.78 (1.23 – 6.27)]
than those who are currently working, 3) diabetic patients
with multiple additional illnesses were more likely to have
depression [O.R = 1.81 (1.05 – 3.11)] than those with ≤ 1
additional illness, and finally 4) diabetic patients with high
medication adherence score were less likely to have de-
pression [O.R = 0.31 (0.18 – 0.53)] than those with low
(< 6) medication adherence score.
Discussion
This study investigated the prevalence of depression
among adult Palestinian type II diabetic patients and
identified demographic and disease-related risk factors
for depression. Our study showed that 40% of the
screened patients are potential cases of depression. It
should be emphasized that high BDI II scores presented
in this study are not diagnostic of depression. Rather,
high scores are indicative of the presence of depressive
symptoms and further clinical consultation to establish
definitive diagnosis of depression is needed. In our study,
most patients who are potential cases of depression were
females, had multiple additional illnesses, currently job-
less, had low educational level, had low medication ad-
herence, and had an abnormally high BMI. However,
multivariate analysis showed that the only significant
predictors of depression were low education, having no
current job, having multiple additional illnesses, and
having low medication adherence. Many research groups
have investigated the relationship between diabetes mel-
litus and depression. Some research groups indicated
that depression is highly prevalent among diabetics and
the risk of depression might be increased in the presence
of other co-morbid conditions [11,32-38]. Compared to
other published studies, our results reported higher
prevalence rate of depression among diabetics. A meta-
analysis of 42 published studies found that the preva-
lence of major depression among diabetic patients was
11% and the prevalence of clinically serious depression
was 31% [39]. A study in Jordan found that the preva-
lence rate of undiagnosed depression among Jordanian
diabetic patients was 19.7% [17]. A meta-analysis study
held in the United States found that the prevalence rate
of depression among adult diabetic patients ranging
from 3.8% to 27.3% [39]. Other studies reported a preva-
lence rates of 5.4% [40], 8% [41], 32.4% [42] and 41.3%
[43]. One possible reason for the differences in the
prevalence of depression among diabetic patients re-
ported by different studies is the use of different scales
Table 1 Univariate analysis of factors associated with depression
Variable Total BDI-II depression score Unadjusted OR P-value
N = 294
(95% CI)≥ 16 < 16
N = 120 N = 174
Age (years)
≤ 65 216 (73.5%) 85 (39.4%) 131 (60.6%) 0.8 (0.5 – 1.3) 0.40
> 65 78 (26.5%) 35 (44.9%) 43 (55.1%) Reference
Gender
Male 130 (44.2%) 43 (33.1%) 87 (66.9%) Reference 0.02
Female 164 (55.8%) 77 (47.0%) 87 (53.0%) 1.8 (1.1 – 2.9)
Education
Illiterate 87 (29.6%) 47 (39.2%) 40 (23.0%) Reference
Elementary 126 (42.9%) 53 (44.2%) 73 (42.0%) 0.6 (0.4 – 1.1) 0.08
High school 41 (13.9%) 13 (10.80%) 28 (16.1%) 0.4 (0.2 – 0.9) 0.02
College 40 (13.6%) 7 (5.8%) 33 (19.0%) 0.2 (0.1 – 0.5) < 0.01
Marital status
Married 243 (82.7%) 101 (41.6%) 142 (58.4%) 1.2 (0.6 – 2.2) 0.58
Others 51 (17.3%) 19 (37.3%) 32 (62.7%) Reference
Currently smoking
Yes 71 (24.1%) 32 (45.1%) 39 (54.9%) 1.3 (0.7 – 2.2) 0.40
No 166 (56.5%) 79 (47.6%) 84 (52.4%) Reference
Working
Yes 62 (21.1%) 12 (19.4%) 50 (80.6%) Reference < 0.01
No 232 (78.9%) 108 (46.6%) 124 (53.4%) 3.6 (1.8 – 7.7)
Duration of illness 10 (5 – 16) 12 (6 – 16.75) 10 (5 – 15) 1.0 (0.9 – 1.05) 0.32
Number of additional illness
≤ 1 114 (38.8%) 36 (31.6%) 78 (68.4%) Reference 0.01
≥ 2 180 (61.2%) 84 (46.9%) 96 (53.3%) 1.9 (1.2 – 3.1)
Number of anti-diabetic medication
≤ 1 112 (38.1%) 44 (39.3%) 68 (60.7%) Reference 0.68
≥ 2 182 (61.9%) 76 (41.8%) 106 (58.2%) 1.1 (0.7 – 1.8)
Insulin use
Yes 147 (50%) 64 (43.5%) 83 (56.5%) 1.25 (0.8 – 2.0) 0.34
No 147 (50%) 56 (38.1%) 91 (61.9%) Reference
HbA1C
< 7 52 (17.7%) 23 (44.2%) 29 (55.8%) Reference 0.58
≥ 7 242 (82.3%) 97 (40.1%) 145 (59.9%) 0.8 (0.5 – 1.5)
Medication adherence score
< 6 167 (56.8%) 86 (51.5%) 81 (48.5%) Reference < 0.01
≥ 6 127 (43.2%) 34 (26.8%) 91 (73.2%) 0.3 (0.2 – 0.6)
BMI
< 25 30 (10.2%) 7 (23.3%) 23 (76.7%) Reference
25 – 29 98 (33.3%) 34 (34.7%) 64 (65.3%) 1.8 (0.7 – 4.5) 0.25
≥ 30 166 (56.5%) 79 (47.6%) 84 (52.4%) 3.0 (1.2 – 7.3) 0.02
Abbreviations: CI confidence interval, BDI-II Beck Depression Inventory – Second edition, BMI Body Mass Index, MMAS-8 Morisky Medication Adherence Scale–8
items, OR Odds Ratio, HbA1C Glycated Hemoglobin.
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Table 2 Multivariate analysis of factors associated with depression
Variables β S.E. Wald p-value Odds ratio with 95% CI
Gender Female Reference
Male -0.04 0.31 0.02 0.898 0.96 (0.52-1.77)
Education Illiterate Reference
Elementary -0.33 0.31 1.15 0.284 0.72 (0.39- 0.32)
High school -0.85 0.45 3.61 0.057 0.43 (0.18- 1.03)
College -1.42 0.52 7.57 0.006 0.24 (0.09-0.66)
Occupation Yes Reference
No 1.02 0.42 6.05 0.014 2.78 (1.23-6.27)
Additional illness ≤ 1 Reference
≥ 2 0.59 0.28 4.55 0.033 1.81 (1.05-3.11)
BMI < 25 Reference
25 - < 30 0.50 0.52 0.92 0.336 1.65 (0.60-4.58)
≥ 30 0.86 0.50 3.00 0.083 2.36 (0.90-6.23)
Medication adherence score < 6 Reference
≥ 6 -1.17 0.27 14.17 0.001 0.31 (0.18- 0.53)
Abbreviations: CI confidence interval, β coefficient of predictor variables, BMI Body Mass Index, MMAS-8 Morisky Medication Adherence Scale–8 items,
OR Odds Ratio.
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used the PHQ-8, others used Ham-D or BDI II scales.
The increased vulnerability to depression in individuals
with type 2 diabetes is not yet clearly understood. How-
ever, depression involves physiological changes of the neu-
roendocrine system. The underlying cause of depression is
thought to be related to changes in the neurotransmitters
in the brain such as serotonin (5-HT), dopamine (DA),
and norepinephrine (NE) which are monoamine neuro-
transmitters which affect mood and behavior. It is believed
that during psychological stress counter regulatory hor-
mones such as catecholamine a neurotransmitter, gluco-
corticoids, growth hormones, and glucagons are activated
[44]. The activation of the counter regulatory hormones
interferes in the action of insulin which is not able to
lower glucose but instead elevates blood glucose. The in-
crease in glucose level creates a greater challenge in main-
taining metabolic control. Poor glycemic control and
functional impairment due to increasing diabetes compli-
cations may cause or worsen depression and lessen the re-
sponse to antidepressant treatment [45]. In spite of the
known devastating effect of depression on diabetes, it was
found that only 31% of patients with diabetes and depres-
sion received adequate antidepressant treatment and only
6% received 4-5 sessions of psychotherapy in a 12 month
period [46]. Studies of the economics of treatment of de-
pression among diabetic patients have yielded positive re-
sults. The health care expenses sustained by individuals
with diabetes and depression are higher than those with
diabetes alone [47,48].
It may be argued that the high prevalence rate of de-
pression found in our study is due to many patientshaving uncontrolled diabetes (82%). However, we did
not find significant relationship between glycemic con-
trol and potential for depression. Studies about the rela-
tionship between depression and poor glycemic control
gave mixed results. A study had shown a negative rela-
tionship between depression and poor glycemic control
and diabetes complications. Worse glycemic control was
observed in depressed adults with diabetes [49]. A meta-
analysis study [50] found that patients with type 1 and
type 2 diabetes and depression persistently had higher
HbA1c levels [50]. Wagner et al. also found higher
HbA1c and more diabetes complications in African
Americans with higher depressive symptoms after con-
trolling for confounders between depression and HbA1c
levels [51]. In a prospective representative study of pa-
tients with type 2 diabetes, depression predicted prob-
lems with medication adherence, and unsatisfactory
glycemic control [52]. Diabetic complications and mor-
tality were also found to be greater among depressed pa-
tients [14,53,54]. The microvascular and macrovascular
complications of diabetes are augmented by the presence
of depression in diabetes thus contributing to the in-
creased mortality rate in this population [55]. In con-
trast, other investigators found no relationship between
depression and diabetic complications [42,56-58]. Cross-
sectional studies found a significant positive correlation
between depressive symptoms and HbA1c in patients
with Type 1 diabetes but no significant correlation in pa-
tients with Type 2 diabetes [59-61], indicating that de-
pression affects glycemic control in patients with Type 1
but not Type 2 diabetes. In support of this, a study
found that patients with Type 1 but not Type 2 diabetes
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control than their counterparts who had no depression
[62,63]. A study showed that changes in depressive
symptoms were not associated with changes in HbA1c
or fasting glucose levels over a 1-year period in either
patients with Type 1 or Type 2 diabetes [63].
Our study showed that approximately two thirds of
those who scored ≥ 16 points were females. The higher
prevalence of depression among females is in consist-
ence with other studies [17,35,55,64,65]. In a meta-
analysis, Anderson et al found that diabetes doubles the
risk of depression and it is especially more among fe-
males [39]. However, not all studies reported this gender
differences in depression [58]. Our results indicated that
about 90% of the total sample was either overweight or
obese (had a BMI > 25). The BDI score was significantly
higher among obese patients. A study found that depres-
sion was more common among diabetic women espe-
cially if they were overweight and that body weight was
a predictor of depression more than diabetes itself [66].
Similarly, recent studies have found that higher BMI was
a predictor of depression in type 2diabetes [64,67]. High
educational level decreases the odds of being classified
as depressed patients which is similar to findings pub-
lished in other studies [13,17]. Medication adherence
showed a significant relationship with depression. Ad-
herent patients are associated with lower odds of being
depressed. It has been reported by other researchers that
depressed diabetic patients do not pay much effort on
daily management activities [68,69] and this result is
consistent with many studies that reported that de-
pressed diabetic patients are likely to have physical limi-
tations and a poor quality of life [70-73], bearing in
mind that self-care behaviors in diabetes include adher-
ence to dietary restrictions and medications, adequate
physical exercise and blood glucose monitoring [68,69].
Management guidelines for diabetes mellitus emphasize
the importance of medication adherence, physical ac-
tivity, diet and self-monitoring of blood glucose [74].
Gonzalez et al. proposed that the presence of depressive
symptoms are good predictors of poor adherence to self-
care particularly in adherence to medications and diet
and exercise regimens [75]. A systematic review of treat-
ment adherence among individuals with diabetes and
depression indicated that there was a significant rela-
tionship between depression and treatment non-
adherence [75]. Finally, our study indicated that having
no work is significantly associated with depression
score ≥ 16 points. This is expected since having no work
is by itself a depressing factor.
In contrast to some other studies, our study showed no
significant association between depression score and age
among diabetic patients [76]. Furthermore, our study
showed no significant association between depressionand the use of insulin which is contrary to other pub-
lished studies [11]. A study reported that delayed initi-
ation of insulin in type 2 makes a significant number of
diabetic patients vulnerable to diabetic complications and
its adverse outcomes, including depression [77]. Our
study found that the duration of DM was not significantly
associated with depression which is consistent with the
findings reported by other studies [78,79]. However, be-
cause the incidence of diabetic complication increases
with increased illness duration, one could expect greater
depression risk in those who have been ill for a longer
time. Some research groups reported a significantly higher
rate of depression in individual with long standing history
of diabetes than in the newly diagnosed diabetic [80].
Our study is the first to be conducted in Palestine to
determine the prevalence of undiagnosed depression
among diabetic patients. However, our study has few lim-
itations. First, this study is cross-sectional where causal
relationship between diabetes and depression cannot be
established. Variables identified as significantly associated
with depression may precede depression, but in some
cases, these variables could also occur as a result of de-
pression; thus, high scores of BDI II among diabetic pa-
tients must be interpreted with caution. Further studies
with longitudinal prospective design and the presence of
age and gender matched group is needed to shed more
light on the potential relationship between depression
and diabetes mellitus. It is important to state that depres-
sion screening measures provide an estimation of the se-
verity of depressive symptoms and assess the severity
within a specific period of time but they do not diagnose
depression. However, those who score high in depression
measure scales need to interviewed and assessed for a
confirmation of depression. The second limitation of this
study was its partial reliance on self-report for its mea-
sures, including depression and medication adherence;
therefore, a clinical interview to assess depression maybe
a superior measure because of its higher level of specifi-
city. Accordingly, a longitudinal clinical study of a
community-based sample using clinical symptoms for
diagnosis of depression is needed to assess the relation-
ship between various variables including diabetes control.
Third limitation of this study was HbA1c measurement.
The presence of many clinically silent hemoglobin vari-
ants might cause deviation in the HbA1c results leading
to falsely high or low values [81,82]. Therefore, the accur-
acy of the results and validity of the HbA1c interpretation
cannot be assured. Finally, gender differences in risk of
depression among diabetic patients need further investi-
gation using large sample size is needed since univariate
analysis showed such gender differences with higher risk
among females. Community-based study among diabetic
women will be of great value given that women are more
prone to depression than men.
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The prevalence of depression among Palestinian diabetic
patients is higher than reported in other communities and
has never been approached before. Being a female, not ad-
herent to anti-diabetic medications, having low educa-
tional level and being jobless were significant predictors
and are associated with an increased likelihood of develop-
ing major depressive disorders. We highly recommend the
introduction of the psychological aspect among the dia-
betic health care plan to reduce the number of the de-
pressed or the misrecognized depressed diabetic patients
and consequently offer them a better quality of life.
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